Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (15)

Search Parameters:
Authors = M. Niccolo

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
21 pages, 7532 KiB  
Article
Outcomes of Radiotherapy in Oligoprogressive Breast Cancer
by Fabio Marazzi, Valeria Masiello, Armando Orlandi, Francesca Moschella, Silvia Chiesa, Alba Di Leone, Giovanna Garufi, Ciro Mazzarella, Alejandro M. Sanchez, Calogero Casa, Angela Bucaro, Flavia De Lauretis, Niccolo Borghesan, Luca Tagliaferri, Gianluca Franceschini, Emilio Bria, Riccardo Masetti, Alessandra Fabi, Cynthia Aristei, Giampaolo Tortora, Vincenzo Valentini and Maria A. Gambacortaadd Show full author list remove Hide full author list
J. Pers. Med. 2024, 14(8), 805; https://doi.org/10.3390/jpm14080805 - 29 Jul 2024
Cited by 1 | Viewed by 1745
Abstract
Introduction: Radiotherapy (RT) shows potential for improving local control in cases of oligoprogressive metastatic breast cancer (mBC). This retrospective analysis aims to evaluate the advantages of RT in such a clinical scenario. Methods: We conducted a retrospective analysis including patients with mBC who [...] Read more.
Introduction: Radiotherapy (RT) shows potential for improving local control in cases of oligoprogressive metastatic breast cancer (mBC). This retrospective analysis aims to evaluate the advantages of RT in such a clinical scenario. Methods: We conducted a retrospective analysis including patients with mBC who received radiation therapy (RT) for up to three sites of oligoprogression while continuing systemic therapy. The study took place between January 2014 and December 2021. Our endpoints were progression-free survival after radiotherapy (PFS-AR), the rate of discontinuation of systemic therapy (RDT) at three months post-RT, and overall survival (OS). We used Cox regression analysis to perform multivariate analysis for PFS-AR. Results: Fifty-nine patients met the inclusion criteria. The PFS-AR was 13 months (95% CI 8.5–18.8 months). At three months, the RDT was 3% (two patients). A significant difference in median PFS-AR was observed between patients in the first + second-line group and those in the subsequent line group (p = 0.03). In the multivariate analysis conducted for PFS-AR, the biologically effective dose (BED) with α/β = 4 > 100 Gy emerged as the sole significant variable (p = 0.0017). The median overall survival (OS) was 24.4 months (95% CI 17–24.4 months). Conclusions: This study is the first report on the outcomes of radiotherapy in a cohort of over 50 patients with oligoprogressive metastatic breast cancer (mBC). Our findings emphasize the significant relationship between PFS-AR, the number of ongoing lines of systemic therapy, and the BED of radiotherapy. Full article
(This article belongs to the Special Issue New Insights into Personalized Surgical Oncology)
Show Figures

Figure 1

15 pages, 1770 KiB  
Article
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience
by Alejandro M. Sanchez, Flavia De Lauretis, Angela Bucaro, Niccolo Borghesan, Chiara V. Pirrottina, Antonio Franco, Lorenzo Scardina, Diana Giannarelli, Jenny C. Millochau, Marina L. Parapini, Alba Di Leone, Fabio Marazzi, Armando Orlandi, Antonella Palazzo, Alessandra Fabi, Riccardo Masetti and Gianluca Franceschini
J. Clin. Med. 2024, 13(13), 3665; https://doi.org/10.3390/jcm13133665 - 23 Jun 2024
Cited by 1 | Viewed by 2025
Abstract
Background: Oncoplastic surgery (OPS) reliability in the post-neoadjuvant chemotherapy (NACT) setting is still debated due to weak scientific evidences in such scenarios. Methods: Our analysis aims to report results obtained in a retrospective series of 111 patients consecutively treated with level II OPS [...] Read more.
Background: Oncoplastic surgery (OPS) reliability in the post-neoadjuvant chemotherapy (NACT) setting is still debated due to weak scientific evidences in such scenarios. Methods: Our analysis aims to report results obtained in a retrospective series of 111 patients consecutively treated with level II OPS after NACT at the Multidisciplinary Breast Center of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS between 1998 and 2018. The surgical endpoints were the mean specimen volume, rates of positive margins (PMR), re-excision (RR), conversion to mastectomy (CMR), and complications (CR). The oncological endpoints were overall survival (OS), disease-free survival (DFS), and local recurrence (LR). To evaluate the impact of NACT on surgical and oncological outcomes at 302 months, we conducted a propensity score matching, pairing patients in post-NACT and upfront surgery groups. Results: The mean sample volume was 390,796 mm3. We registered a 3.6% of PMR, 1.8% RR, 0.9% CMR, 5% CR. The 10-year OS and 10-year DFS with a median follow-up of 88 months (6–302) were 79% and 76%, respectively, with an LR recurrence rate of 5%. The post-NACT group received significantly larger excised volumes and lower PMR. NACT did not affect surgical and oncological outcomes. Conclusions: Level II OPS can be considered a reliable alternative to mastectomy even in the post-NACT setting. Full article
Show Figures

Figure 1

17 pages, 4330 KiB  
Article
Segmentation and Multi-Timepoint Tracking of 3D Cancer Organoids from Optical Coherence Tomography Images Using Deep Neural Networks
by Francesco Branciforti, Massimo Salvi, Filippo D’Agostino, Francesco Marzola, Sara Cornacchia, Maria Olimpia De Titta, Girolamo Mastronuzzi, Isotta Meloni, Miriam Moschetta, Niccolò Porciani, Fabrizio Sciscenti, Alessandro Spertini, Andrea Spilla, Ilenia Zagaria, Abigail J. Deloria, Shiyu Deng, Richard Haindl, Gergely Szakacs, Agnes Csiszar, Mengyang Liu, Wolfgang Drexler, Filippo Molinari and Kristen M. Meiburgeradd Show full author list remove Hide full author list
Diagnostics 2024, 14(12), 1217; https://doi.org/10.3390/diagnostics14121217 - 8 Jun 2024
Cited by 3 | Viewed by 3313
Abstract
Recent years have ushered in a transformative era in in vitro modeling with the advent of organoids, three-dimensional structures derived from stem cells or patient tumor cells. Still, fully harnessing the potential of organoids requires advanced imaging technologies and analytical tools to quantitatively [...] Read more.
Recent years have ushered in a transformative era in in vitro modeling with the advent of organoids, three-dimensional structures derived from stem cells or patient tumor cells. Still, fully harnessing the potential of organoids requires advanced imaging technologies and analytical tools to quantitatively monitor organoid growth. Optical coherence tomography (OCT) is a promising imaging modality for organoid analysis due to its high-resolution, label-free, non-destructive, and real-time 3D imaging capabilities, but accurately identifying and quantifying organoids in OCT images remain challenging due to various factors. Here, we propose an automatic deep learning-based pipeline with convolutional neural networks that synergistically includes optimized preprocessing steps, the implementation of a state-of-the-art deep learning model, and ad-hoc postprocessing methods, showcasing good generalizability and tracking capabilities over an extended period of 13 days. The proposed tracking algorithm thoroughly documents organoid evolution, utilizing reference volumes, a dual branch analysis, key attribute evaluation, and probability scoring for match identification. The proposed comprehensive approach enables the accurate tracking of organoid growth and morphological changes over time, advancing organoid analysis and serving as a solid foundation for future studies for drug screening and tumor drug sensitivity detection based on organoids. Full article
(This article belongs to the Special Issue Optical Coherence Tomography (OCT): State of the Art)
Show Figures

Figure 1

12 pages, 1783 KiB  
Article
Cannabis Virome Reconstruction and Antiviral RNAi Characterization through Small RNA Sequencing
by Niccolo’ Miotti, Natalia Sukhikh, Nathalie Laboureau, Paola Casati and Mikhail M. Pooggin
Plants 2023, 12(23), 3925; https://doi.org/10.3390/plants12233925 - 21 Nov 2023
Cited by 4 | Viewed by 1690
Abstract
Viral infections pose an emerging threat to hemp (Cannabis sativa) cultivation. We used Illumina small (s)RNA sequencing for virome reconstruction and characterization of antiviral RNA interference (RNAi) in monoecious and dioecious hemp varieties, which exhibited different virus-like symptoms. Through de novo [...] Read more.
Viral infections pose an emerging threat to hemp (Cannabis sativa) cultivation. We used Illumina small (s)RNA sequencing for virome reconstruction and characterization of antiviral RNA interference (RNAi) in monoecious and dioecious hemp varieties, which exhibited different virus-like symptoms. Through de novo and reference-based sRNA assembly, we identified and reconstructed Cannabis cryptic virus (family Partitiviridae), Cannabis sativa mitovirus 1 (Mitoviridae) and Grapevine line pattern virus (Bromoviridae) as well as a novel virus tentatively classified into Partitiviridae. Members of both Partitiviridae and Bromoviridae were targeted by antiviral RNAi, generating 21 nt and, less abundant, 22 nt sRNAs from both strands of the entire virus genome, suggesting the involvement of Dicer-like (DCL) 4 and DCL2 in viral sRNA biogenesis, respectively. Mitovirus sRNAs represented predominantly the positive-sense strand and had a wider size range, with the 21 nt class being most abundant on both strands. For all viruses, 21 and 22 nt sRNAs had predominantly 5′-terminal uridine or cytosine, suggesting their binding to antiviral Argonaute (AGO) 1 and AGO5, respectively. As no clear association of any virus with symptoms was observed, further studies should clarify if these viruses individually or in combination can cause hemp diseases. Full article
(This article belongs to the Special Issue Different Aspects of Plant Viral Metagenomics)
Show Figures

Figure 1

9 pages, 722 KiB  
Case Report
Unraveling the Neurological Complexity of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, and Skin Changes Syndrome: A Report of a Challenging Case of a Young Woman and Cutting-Edge Advancements in the Field
by Gioconda Furciniti, Giuseppe Casalino, Francesco M. Lo Russo, Niccolò Bolli, Megi Meneri, Giacomo P. Comi, Stefania P. Corti and Daniele Velardo
Diseases 2023, 11(4), 167; https://doi.org/10.3390/diseases11040167 - 10 Nov 2023
Viewed by 2578
Abstract
POEMS syndrome—characterized by polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes—is an uncommon and complex paraneoplastic disorder encompassing a diverse array of symptoms. Here we report the challenging case of a 34-year-old female who sought medical attention at the emergency department due to distal [...] Read more.
POEMS syndrome—characterized by polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes—is an uncommon and complex paraneoplastic disorder encompassing a diverse array of symptoms. Here we report the challenging case of a 34-year-old female who sought medical attention at the emergency department due to distal lower limb weakness. She was breastfeeding her first child at that time. Her condition rapidly deteriorated, making it difficult for her to perform simple tasks independently. Initially, she struggled with activities like jumping or climbing stairs. Eventually, her ability to walk was also compromised. These symptoms underscored the swift evolution of her polyneuropathy. Nerve conduction studies and electromyography confirmed a diagnosis of mixed demyelinating and axonal polyneuropathy. Subsequent investigations, including bone marrow biopsy and immunochemistry testing, revealed a plasma cell disorder characterized by lambda monoclonal gammopathy, along with elevated levels of vascular endothelial growth factor (VEGF > 8000 pg/mL). This pivotal finding led to the diagnosis of POEMS syndrome, prompting the initiation of antineoplastic therapy (daratumumab-lenalidomide-dexamethasone) to manage this condition. An autologous cell transplantation was planned. The rarity of POEMS syndrome and its diverse clinical manifestations often lead to an incorrect or delayed diagnosis. Our case underscores the importance of considering this syndrome in patients presenting with acute or subacute polyneuropathy, even if the patients are young. In conclusion, this case elucidates the diagnostic complexities of POEMS syndrome, emphasizing the integral role of comprehensive multidisciplinary evaluations and the potential influence of increased VEGF as a diagnostic key element and possible therapeutic target. Full article
Show Figures

Figure 1

12 pages, 2334 KiB  
Article
The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
by Natalia Platonova, Elisa Lazzari, Michela Colombo, Monica Falleni, Delfina Tosi, Domenica Giannandrea, Valentina Citro, Lavinia Casati, Domenica Ronchetti, Niccolò Bolli, Antonino Neri, Federica Torricelli, Leslie A. Crews, Catriona H. M. Jamieson and Raffaella Chiaramonte
Int. J. Mol. Sci. 2023, 24(19), 14558; https://doi.org/10.3390/ijms241914558 - 26 Sep 2023
Cited by 1 | Viewed by 1864
Abstract
The NOTCH ligands JAG1 and JAG2 have been correlated in vitro with multiple myeloma (MM) cell proliferation, drug resistance, self-renewal and a pathological crosstalk with the tumor microenvironment resulting in angiogenesis and osteoclastogenesis. These findings suggest that a therapeutic approach targeting JAG ligands [...] Read more.
The NOTCH ligands JAG1 and JAG2 have been correlated in vitro with multiple myeloma (MM) cell proliferation, drug resistance, self-renewal and a pathological crosstalk with the tumor microenvironment resulting in angiogenesis and osteoclastogenesis. These findings suggest that a therapeutic approach targeting JAG ligands might be helpful for the care of MM patients and lead us to explore the role of JAG1 and JAG2 in a MM in vivo model and primary patient samples. JAG1 and JAG2 protein expression represents a common feature in MM cell lines; therefore, we assessed their function through JAG1/2 conditional silencing in a MM xenograft model. We observed that JAG1 and JAG2 showed potential as therapeutic targets in MM, as their silencing resulted in a reduction in the tumor burden. Moreover, JAG1 and JAG2 protein expression in MM patients was positively correlated with the presence of MM cells in patients’ bone marrow biopsies. Finally, taking advantage of the Multiple Myeloma Research Foundation (MMRF) CoMMpass global dataset, we showed that JAG2 gene expression level was a predictive biomarker associated with patients’ overall survival and progression-free survival, independently from other main molecular or clinical features. Overall, these results strengthened the rationale for the development of a JAG1/2-tailored approach and the use of JAG2 as a predictive biomarker in MM. Full article
Show Figures

Figure 1

15 pages, 2468 KiB  
Article
Loss-of-Function Variants in DRD1 in Infantile Parkinsonism-Dystonia
by Kimberley M. Reid, Dora Steel, Sanjana Nair, Sanjay Bhate, Lorenzo Biassoni, Sniya Sudhakar, Michelle Heys, Elizabeth Burke, Erik-Jan Kamsteeg, Genomics England Research Consortium, Biju Hameed, Michael Zech, Niccolo E. Mencacci, Katy Barwick, Maya Topf and Manju A. Kurian
Cells 2023, 12(7), 1046; https://doi.org/10.3390/cells12071046 - 30 Mar 2023
Cited by 7 | Viewed by 3588
Abstract
The human dopaminergic system is vital for a broad range of neurological processes, including the control of voluntary movement. Here we report a proband presenting with clinical features of dopamine deficiency: severe infantile parkinsonism-dystonia, characterised by frequent oculogyric crises, dysautonomia and global neurodevelopmental [...] Read more.
The human dopaminergic system is vital for a broad range of neurological processes, including the control of voluntary movement. Here we report a proband presenting with clinical features of dopamine deficiency: severe infantile parkinsonism-dystonia, characterised by frequent oculogyric crises, dysautonomia and global neurodevelopmental impairment. CSF neurotransmitter analysis was unexpectedly normal. Triome whole-genome sequencing revealed a homozygous variant (c.110C>A, (p.T37K)) in DRD1, encoding the most abundant dopamine receptor (D1) in the central nervous system, most highly expressed in the striatum. This variant was absent from gnomAD, with a CADD score of 27.5. Using an in vitro heterologous expression system, we determined that DRD1-T37K results in loss of protein function. Structure-function modelling studies predicted reduced substrate binding, which was confirmed in vitro. Exposure of mutant protein to the selective D1 agonist Chloro APB resulted in significantly reduced cyclic AMP levels. Numerous D1 agonists failed to rescue the cellular defect, reflected clinically in the patient, who had no benefit from dopaminergic therapy. Our study identifies DRD1 as a new disease-associated gene, suggesting a crucial role for the D1 receptor in motor control. Full article
Show Figures

Figure 1

17 pages, 4573 KiB  
Article
Optimal Balance between Heating, Cooling and Environmental Impacts: A Method for Appropriate Assessment of Building Envelope’s U-Value
by Safieddine Ounis, Niccolò Aste, Federico M. Butera, Claudio Del Pero, Fabrizio Leonforte and Rajendra S. Adhikari
Energies 2022, 15(10), 3570; https://doi.org/10.3390/en15103570 - 13 May 2022
Cited by 14 | Viewed by 3251
Abstract
In Europe, the recent application of regulations oriented to zero-energy buildings and climate neutrality in 2050 has led to a reduction in energy consumption for heating and cooling in the construction sector. The thermal insulation of the building envelope plays a key role [...] Read more.
In Europe, the recent application of regulations oriented to zero-energy buildings and climate neutrality in 2050 has led to a reduction in energy consumption for heating and cooling in the construction sector. The thermal insulation of the building envelope plays a key role in this process and the requirements about the maximum allowable thermal transmittance are defined by country-specific guidelines. Typically, high insulation values provide low energy consumption for heating; however, they may also entail a risk of overheating in summer period and thus negatively affect the overall performance of the building. In addition, the embodied energy and related emissions caused by the manufacturing and transportation processes of thermal insulation cannot be further neglected in the evaluation of the best optimal solution. Therefore, this paper aims to evaluate the influence in terms of embodied and operational energy of various walls’ thermal insulation thicknesses on residential buildings in Europe. To this end, the EnergyPlus engine was used for the energy simulation within the Ladybug and Honeybee tools, by parametrically conducting multiple iterations; 53 variations of external wall U-value, considering high- and low-thermal-mass scenarios, were simulated for 100 representative cities of the European context, using a typical multifamily building as a reference. The results demonstrate that massive walls generally perform better than lightweight structures and the best solution in terms of energy varies according to each climate. Accordingly, the wall’s thermal transmittance for the samples of Oslo, Bordeaux, Rome and Almeria representative of the Continental, oceanic temperate, Mediterranean, and hot, semi-arid climates were, respectively: 0.12, 0.26, 0.42, and 0.64 W/m2K. The optimal solutions are graphically reported on the map of Europe according to specific climatic features, providing a guidance for new constructions and building retrofit. Full article
(This article belongs to the Section G: Energy and Buildings)
Show Figures

Figure 1

12 pages, 1044 KiB  
Article
Pan-Piscine Orthoreovirus (PRV) Detection Using Reverse Transcription Quantitative PCR
by Julie Zhao, Niccolò Vendramin, Argelia Cuenca, Mark Polinski, Laura M. Hawley and Kyle A. Garver
Pathogens 2021, 10(12), 1548; https://doi.org/10.3390/pathogens10121548 - 27 Nov 2021
Cited by 8 | Viewed by 3412
Abstract
Piscine orthoreovirus (PRV) infects farmed and wild salmon and trout species in North America, South America, Europe, and East Asia. PRV groups into three distinct genotypes (PRV-1, PRV-2, and PRV-3) that can vary in distribution, host specificity, and/or disease potential. Detection of the [...] Read more.
Piscine orthoreovirus (PRV) infects farmed and wild salmon and trout species in North America, South America, Europe, and East Asia. PRV groups into three distinct genotypes (PRV-1, PRV-2, and PRV-3) that can vary in distribution, host specificity, and/or disease potential. Detection of the virus is currently restricted to genotype specific assays such that surveillance programs require the use of three assays to ensure universal detection of PRV. Consequently, herein, we developed, optimized, and validated a real-time reverse transcription quantitative PCR assay (RT-qPCR) that can detect all known PRV genotypes with high sensitivity and specificity. Targeting a conserved region at the 5′ terminus of the M2 segment, the pan-PRV assay reliably detected all PRV genotypes with as few as five copies of RNA. The assay exclusively amplifies PRV and does not cross-react with other salmonid viruses or salmonid host genomes and can be performed as either a one- or two-step RT-qPCR. The assay is highly reproducible and robust, showing 100% agreement in test results from an inter-laboratory comparison between two laboratories in two countries. Overall, as the assay provides a single test to achieve highly sensitive pan-specific PRV detection, it is suitable for research, diagnostic, and surveillance purposes. Full article
(This article belongs to the Special Issue Advances in Fish Virology: Emerging Viruses and Novel Techniques)
Show Figures

Figure 1

250 pages, 84542 KiB  
Article
Deep Underground Neutrino Experiment (DUNE) Near Detector Conceptual Design Report
by A. Abed Abud, B. Abi, R. Acciarri, M. A. Acero, G. Adamov, D. Adams, M. Adinolfi, A. Aduszkiewicz, Z. Ahmad, J. Ahmed, T. Alion, S. Alonso Monsalve, M. Alrashed, C. Alt, A. Alton, P. Amedo, J. Anderson, C. Andreopoulos, M. P. Andrews, F. Andrianala, S. Andringa, N. Anfimov, A. Ankowski, M. Antonova, S. Antusch, A. Aranda-Fernandez, A. Ariga, L. O. Arnold, M. A. Arroyave, J. Asaadi, A. Aurisano, V. Aushev, D. Autiero, M. Ayala-Torres, F. Azfar, A. Back, H. Back, J. J. Back, C. Backhouse, P. Baesso, I. Bagaturia, L. Bagby, S. Balasubramanian, P. Baldi, B. Baller, B. Bambah, F. Barao, G. Barenboim, G. J. Barker, W. Barkhouse, C. Barnes, G. Barr, J. Barranco Monarca, N. Barros, J. L. Barrow, A. Basharina-Freshville, A. Bashyal, V. Basque, E. Belchior, J. B. R. Battat, F. Battisti, F. Bay, J. L. Bazo Alba, J. F. Beacom, E. Bechetoille, B. Behera, L. Bellantoni, G. Bellettini, V. Bellini, O. Beltramello, D. Belver, N. Benekos, F. Bento Neves, S. Berkman, P. Bernardini, R. M. Berner, H. Berns, S. Bertolucci, M. Betancourt, A. Betancur Rodríguez, M. Bhattacharjee, S. Bhuller, B. Bhuyan, S. Biagi, J. Bian, M. Biassoni, K. Biery, B. Bilki, M. Bishai, A. Bitadze, A. Blake, F. D. M. Blaszczyk, G. C. Blazey, E. Blucher, J. Boissevain, S. Bolognesi, T. Bolton, L. Bomben, M. Bonesini, M. Bongrand, F. Bonini, A. Booth, C. Booth, S. Bordoni, A. Borkum, T. Boschi, N. Bostan, P. Bour, C. Bourgeois, S. B. Boyd, D. Boyden, J. Bracinik, D. Braga, D. Brailsford, A. Brandt, J. Bremer, C. Brew, E. Brianne, S. J. Brice, C. Brizzolari, C. Bromberg, G. Brooijmans, J. Brooke, A. Bross, G. Brunetti, M. Brunetti, N. Buchanan, H. Budd, I. Cagnoli, D. Caiulo, P. Calafiura, J. Calcutt, M. Calin, S. Calvez, E. Calvo, A. Caminata, M. Campanelli, K. Cankocak, D. Caratelli, G. Carini, B. Carlus, P. Carniti, I. Caro Terrazas, H. Carranza, T. Carroll, J. F. Castaño Forero, A. Castillo, C. Castromonte, E. Catano-Mur, C. Cattadori, F. Cavalier, F. Cavanna, S. Centro, G. Cerati, A. Cervelli, A. Cervera Villanueva, M. Chalifour, A. Chappell, E. Chardonnet, N. Charitonidis, A. Chatterjee, S. Chattopadhyay, H. Chen, M. Chen, Y. Chen, Z. Chen, D. Cherdack, C. Chi, S. Childress, A. Chiriacescu, G. Chisnall, K. Cho, S. Choate, D. Chokheli, S. Choubey, A. Christensen, D. Christian, G. Christodoulou, A. Chukanov, E. Church, V. Cicero, P. Clarke, T. E. Coan, A. G. Cocco, J. A. B. Coelho, E. Conley, R. Conley, J. M. Conrad, M. Convery, S. Copello, L. Corwin, L. Cremaldi, L. Cremonesi, J. I. Crespo-Anadón, E. Cristaldo, R. Cross, A. Cudd, C. Cuesta, Y. Cui, D. Cussans, M. Dabrowski, O. Dalager, H. da Motta, L. Da Silva Peres, C. David, Q. David, G. S. Davies, S. Davini, J. Dawson, K. De, R. M. De Almeida, P. Debbins, I. De Bonis, M. P. Decowski, A. de Gouvêa, P. C. De Holanda, I. L. De Icaza Astiz, A. Deisting, P. De Jong, A. Delbart, D. Delepine, M. Delgado, A. Dell’Acqua, P. De Lurgio, J. R. T. de Mello Neto, D. M. DeMuth, S. Dennis, C. Densham, G. W. Deptuch, A. De Roeck, V. De Romeri, G. De Souza, R. Dharmapalan, F. Diaz, J. S. Díaz, S. Di Domizio, L. Di Giulio, P. Ding, L. Di Noto, C. Distefano, R. Diurba, M. Diwan, Z. Djurcic, N. Dokania, S. Dolan, M. J. Dolinski, L. Domine, D. Douglas, D. Douillet, G. Drake, F. Drielsma, D. Duchesneau, K. Duffy, P. Dunne, T. Durkin, H. Duyang, O. Dvornikov, D. A. Dwyer, A. S. Dyshkant, M. Eads, A. Earle, D. Edmunds, J. Eisch, L. Emberger, S. Emery, A. Ereditato, C. O. Escobar, G. Eurin, J. J. Evans, E. Ewart, A. C. Ezeribe, K. Fahey, A. Falcone, C. Farnese, Y. Farzan, J. Felix, M. Fernandes Carneiro da Silva, E. Fernandez-Martinez, P. Fernandez Menendez, F. Ferraro, L. Fields, F. Filthaut, A. Fiorentini, R. S. Fitzpatrick, W. Flanagan, B. Fleming, R. Flight, D. V. Forero, J. Fowler, W. Fox, J. Franc, K. Francis, D. Franco, J. Freeman, J. Freestone, J. Fried, A. Friedland, S. Fuess, I. Furic, A. P. Furmanski, A. Gabrielli, A. Gago, H. Gallagher, A. Gallas, A. Gallego-Ros, N. Gallice, V. Galymov, E. Gamberini, T. Gamble, R. Gandhi, R. Gandrajula, F. Gao, S. Gao, D. Garcia-Gamez, M. Á. García-Peris, S. Gardiner, D. Gastler, G. Ge, B. Gelli, A. Gendotti, S. Gent, Z. Ghorbani-Moghaddam, D. Gibin, I. Gil-Botella, S. Gilligan, C. Girerd, A. K. Giri, D. Gnani, O. Gogota, M. Gold, S. Gollapinni, K. Gollwitzer, R. A. Gomes, L. V. Gomez Bermeo, L. S. Gomez Fajardo, F. Gonnella, J. A. Gonzalez-Cuevas, D. Gonzalez-Diaz, M. Gonzalez-Lopez, M. C. Goodman, O. Goodwin, S. Goswami, C. Gotti, E. Goudzovski, C. Grace, M. Graham, R. Gran, E. Granados, P. Granger, A. Grant, C. Grant, D. Gratieri, P. Green, L. Greenler, J. Greer, W. C. Griffith, M. Groh, J. Grudzinski, K. Grzelak, W. Gu, V. Guarino, R. Guenette, E. Guerard, M. Guerzoni, A. Guglielmi, B. Guo, K. K. Guthikonda, R. Gutierrez, P. Guzowski, M. M. Guzzo, S. Gwon, A. Habig, H. Hadavand, R. Haenni, A. Hahn, J. Haiston, P. Hamacher-Baumann, T. Hamernik, P. Hamilton, J. Han, D. A. Harris, J. Hartnell, J. Harton, T. Hasegawa, C. Hasnip, R. Hatcher, K. W. Hatfield, A. Hatzikoutelis, C. Hayes, E. Hazen, A. Heavey, K. M. Heeger, J. Heise, K. Hennessy, S. Henry, M. A. Hernandez Morquecho, K. Herner, L. Hertel, J. Hewes, A. Higuera, T. Hill, S. J. Hillier, A. Himmel, J. Hoff, C. Hohl, A. Holin, E. Hoppe, G. A. Horton-Smith, M. Hostert, A. Hourlier, B. Howard, R. Howell, J. Huang, J. Huang, J. Hugon, G. Iles, N. Ilic, A. M. Iliescu, R. Illingworth, G. Ingratta, A. Ioannisian, L. Isenhower, R. Itay, A. Izmaylov, S. Jackson, V. Jain, E. James, B. Jargowsky, F. Jediny, D. Jena, Y. S. Jeong, C. Jesús-Valls, X. Ji, L. Jiang, S. Jiménez, A. Jipa, R. Johnson, N. Johnston, B. Jones, S. B. Jones, M. Judah, C. K. Jung, T. Junk, Y. Jwa, M. Kabirnezhad, A. Kaboth, I. Kadenko, I. Kakorin, F. Kamiya, N. Kaneshige, G. Karagiorgi, G. Karaman, A. Karcher, M. Karolak, Y. Karyotakis, S. Kasai, S. P. Kasetti, L. Kashur, N. Kazaryan, E. Kearns, P. Keener, K. J. Kelly, E. Kemp, O. Kemularia, W. Ketchum, S. H. Kettell, M. Khabibullin, A. Khotjantsev, A. Khvedelidze, D. Kim, B. King, B. Kirby, M. Kirby, J. Klein, K. Koehler, L. W. Koerner, S. Kohn, P. P. Koller, L. Kolupaeva, M. Kordosky, T. Kosc, U. Kose, V. A. Kostelecký, K. Kothekar, F. Krennrich, I. Kreslo, Y. Kudenko, V. A. Kudryavtsev, S. Kulagin, J. Kumar, P. Kumar, R. Kumar, P. Kunze, N. Kurita, C. Kuruppu, V. Kus, T. Kutter, A. Lambert, B. Land, K. Lande, C. E. Lane, K. Lang, T. Langford, J. Larkin, P. Lasorak, D. Last, C. Lastoria, A. Laundrie, G. Laurenti, A. Lawrence, I. Lazanu, R. LaZur, T. Le, S. Leardini, J. Learned, P. LeBrun, T. LeCompte, G. Lehmann Miotto, R. Lehnert, M. A. Leigui de Oliveira, M. Leitner, L. Li, S. W. Li, T. Li, Y. Li, H. Liao, C. S. Lin, Q. Lin, S. Lin, A. Lister, B. R. Littlejohn, J. Liu, S. Lockwitz, T. Loew, M. Lokajicek, I. Lomidze, K. Long, K. Loo, D. Lorca, T. Lord, J. M. LoSecco, W. C. Louis, X. G. Lu, K. B. Luk, X. Luo, N. Lurkin, T. Lux, V. P. Luzio, D. MacFarlane, A. A. Machado, P. Machado, C. T. Macias, J. R. Macier, A. Maddalena, A. Madera, P. Madigan, S. Magill, K. Mahn, A. Maio, A. Major, J. A. Maloney, G. Mandrioli, R. C. Mandujano, J. Maneira, L. Manenti, S. Manly, A. Mann, K. Manolopoulos, M. Manrique Plata, V. N. Manyam, L. Manzanillas, M. Marchan, A. Marchionni, W. Marciano, D. Marfatia, C. Mariani, J. Maricic, R. Marie, F. Marinho, A. D. Marino, D. Marsden, M. Marshak, C. M. Marshall, J. Marshall, J. Marteau, J. Martin-Albo, N. Martinez, D. A. Martinez Caicedo, S. Martynenko, K. Mason, A. Mastbaum, M. Masud, S. Matsuno, J. Matthews, C. Mauger, N. Mauri, K. Mavrokoridis, I. Mawby, R. Mazza, A. Mazzacane, E. Mazzucato, T. McAskill, E. McCluskey, N. McConkey, K. S. McFarland, C. McGrew, A. McNab, A. Mefodiev, P. Mehta, P. Melas, O. Mena, S. Menary, H. Mendez, D. P. Méndez, A. Menegolli, G. Meng, M. D. Messier, W. Metcalf, T. Mettler, M. Mewes, H. Meyer, T. Miao, G. Michna, T. Miedema, J. Migenda, V. Mikola, R. Milincic, W. Miller, J. Mills, C. Milne, O. Mineev, O. G. Miranda, S. Miryala, C. S. Mishra, S. R. Mishra, A. Mislivec, D. Mladenov, I. Mocioiu, K. Moffat, N. Moggi, R. Mohanta, T. A. Mohayai, N. Mokhov, J. Molina, L. Molina Bueno, A. Montanari, C. Montanari, D. Montanari, E. Montagna, L. M. Montano Zetina, J. Moon, M. Mooney, A. F. Moor, D. Moreno, C. Morris, C. Mossey, E. Motuk, C. A. Moura, J. Mousseau, W. Mu, L. Mualem, J. Mueller, M. Muether, S. Mufson, F. Muheim, A. Muir, M. Mulhearn, D. Munford, H. Muramatsu, S. Murphy, J. Musser, J. Nachtman, S. Nagu, M. Nalbandyan, R. Nandakumar, D. Naples, S. Narita, D. Navas-Nicolás, A. Navrer-Agasson, N. Nayak, M. Nebot-Guinot, K. Negishi, J. K. Nelson, J. Nesbit, M. Nessi, D. Newbold, M. Newcomer, D. Newhart, H. Newton, M. Niccolo, R. Nichol, F. Nicolas-Arnaldos, M. Nicoletta, E. Niner, K. Nishimura, A. Norman, A. Norrick, R. Northrop, P. Novella, J. A. Nowak, M. Oberling, J. P. Ochoa-Ricoux, A. Olivares Del Campo, A. Olivier, A. Olshevskiy, Y. Onel, Y. Onishchuk, J. Ott, L. Pagani, S. Pakvasa, G. Palacio, O. Palamara, S. Palestini, J. M. Paley, M. Pallavicini, C. Palomares, J. L. Palomino-Gallo, E. Pantic, V. Paolone, V. Papadimitriou, R. Papaleo, A. Papanestis, S. Paramesvaran, S. Parke, Z. Parsa, M. Parvu, S. Pascoli, L. Pasqualini, J. Pasternak, J. Pater, C. Patrick, L. Patrizii, R. B. Patterson, S. J. Patton, T. Patzak, A. Paudel, B. Paulos, L. Paulucci, Z. Pavlovic, G. Pawloski, D. Payne, V. Pec, S. J. M. Peeters, E. Pennacchio, A. Penzo, O. L. G. Peres, J. Perry, D. Pershey, G. Pessina, G. Petrillo, C. Petta, R. Petti, F. Piastra, L. Pickering, F. Pietropaolo, R. Plunkett, R. Poling, X. Pons, N. Poonthottathil, F. Poppi, S. Pordes, J. Porter, M. Potekhin, R. Potenza, B. V. K. S. Potukuchi, J. Pozimski, M. Pozzato, S. Prakash, T. Prakash, S. Prince, D. Pugnere, X. Qian, M. C. Queiroga Bazetto, J. L. Raaf, V. Radeka, J. Rademacker, B. Radics, A. Rafique, E. Raguzin, M. Rai, M. Rajaoalisoa, I. Rakhno, A. Rakotonandrasana, L. Rakotondravohitra, Y. A. Ramachers, R. Rameika, M. A. Ramirez Delgado, B. Ramson, A. Rappoldi, G. Raselli, P. Ratoff, S. Raut, R. F. Razakamiandra, J. S. Real, B. Rebel, M. Reggiani-Guzzo, T. Rehak, J. Reichenbacher, S. D. Reitzner, H. Rejeb Sfar, A. Renshaw, S. Rescia, F. Resnati, A. Reynolds, C. Riccio, G. Riccobene, L. C. J. Rice, J. Ricol, A. Rigamonti, Y. Rigaut, D. Rivera, L. Rochester, M. Roda, P. Rodrigues, M. J. Rodriguez Alonso, E. Rodriguez Bonilla, J. Rodriguez Rondon, S. Rosauro-Alcaraz, M. Rosenberg, P. Rosier, B. Roskovec, M. Rossella, J. Rout, P. Roy, S. Roy, A. Rubbia, C. Rubbia, F. C. Rubio, B. Russell, D. Ruterbories, R. Saakyan, S. Sacerdoti, T. Safford, R. Sahay, N. Sahu, P. Sala, N. Samios, O. Samoylov, M. C. Sanchez, D. A. Sanders, D. Sankey, S. Santana, M. Santos-Maldonado, N. Saoulidou, P. Sapienza, C. Sarasty, I. Sarcevic, G. Savage, V. Savinov, A. Scaramelli, A. Scarff, A. Scarpelli, T. Schaffer, H. Schellman, P. Schlabach, D. Schmitz, K. Scholberg, A. Schukraft, E. Segreto, J. Sensenig, I. Seong, A. Sergi, D. Sgalaberna, M. H. Shaevitz, S. Shafaq, M. Shamma, R. Sharankova, H. R. Sharma, R. Sharma, T. Shaw, C. Shepherd-Themistocleous, S. Shin, D. Shooltz, R. Shrock, L. Simard, F. Simon, N. Simos, J. Sinclair, G. Sinev, J. Singh, J. Singh, V. Singh, R. Sipos, F. W. Sippach, G. Sirri, A. Sitraka, K. Siyeon, K. Skarpaas VIII, A. Smith, E. Smith, P. Smith, J. Smolik, M. Smy, E. L. Snider, P. Snopok, M. Soares Nunes, H. Sobel, M. Soderberg, C. J. Solano Salinas, S. Söldner-Rembold, S. Soleti, N. Solomey, V. Solovov, W. E. Sondheim, M. Sorel, J. Soto-Oton, A. Sousa, K. Soustruznik, F. Spagliardi, M. Spanu, J. Spitz, N. J. C. Spooner, K. Spurgeon, R. Staley, M. Stancari, L. Stanco, R. Stanley, R. Stein, H. M. Steiner, J. Stewart, B. Stillwell, J. Stock, F. Stocker, T. Stokes, M. Strait, T. Strauss, S. Striganov, A. Stuart, J. G. Suarez, H. Sullivan, D. Summers, A. Surdo, V. Susic, L. Suter, C. M. Sutera, R. Svoboda, B. Szczerbinska, A. M. Szelc, R. Talaga, H. A. Tanaka, B. Tapia Oregui, A. Tapper, S. Tariq, E. Tatar, R. Tayloe, A. M. Teklu, M. Tenti, K. Terao, C. A. Ternes, F. Terranova, G. Testera, A. Thea, J. L. Thompson, C. Thorn, S. C. Timm, J. Todd, A. Tonazzo, D. Torbunov, M. Torti, M. Tortola, F. Tortorici, D. Totani, M. Toups, C. Touramanis, N. Tosi, R. Travaglini, J. Trevor, S. Trilov, W. H. Trzaska, Y. T. Tsai, Z. Tsamalaidze, K. V. Tsang, N. Tsverava, S. Tufanli, C. Tull, E. Tyley, M. Tzanov, M. A. Uchida, J. Urheim, T. Usher, S. Uzunyan, M. R. Vagins, P. Vahle, G. A. Valdiviesso, E. Valencia, P. Valerio, Z. Vallari, J. W. F. Valle, S. Vallecorsa, R. Van Berg, R. G. Van de Water, F. Varanini, D. Vargas, G. Varner, J. Vasel, S. Vasina, G. Vasseur, N. Vaughan, K. Vaziri, S. Ventura, A. Verdugo, S. Vergani, M. A. Vermeulen, M. Verzocchi, M. Vicenzi, H. Vieira de Souza, C. Vignoli, C. Vilela, B. Viren, T. Vrba, T. Wachala, A. V. Waldron, M. Wallbank, H. Wang, J. Wang, L. Wang, M. H. L. S. Wang, Y. Wang, Y. Wang, K. Warburton, D. Warner, M. Wascko, D. Waters, A. Watson, P. Weatherly, A. Weber, M. Weber, H. Wei, A. Weinstein, D. Wenman, M. Wetstein, A. White, L. H. Whitehead, D. Whittington, M. J. Wilking, C. Wilkinson, Z. Williams, F. Wilson, R. J. Wilson, J. Wolcott, T. Wongjirad, A. Wood, K. Wood, E. Worcester, M. Worcester, C. Wret, W. Wu, W. Wu, Y. Xiao, E. Yandel, G. Yang, K. Yang, S. Yang, T. Yang, A. Yankelevich, N. Yershov, K. Yonehara, T. Young, B. Yu, H. Yu, J. Yu, W. Yuan, R. Zaki, J. Zalesak, L. Zambelli, B. Zamorano, A. Zani, L. Zazueta, G. Zeit, G. P. Zeller, J. Zennamo, K. Zeug, C. Zhang, M. Zhao, E. Zhivun, G. Zhu, P. Zilberman, E. D. Zimmerman, M. Zito, S. Zucchelli, J. Zuklin, V. Zutshi, R. Zwaska and On behalf of the DUNE Collaborationadd Show full author list remove Hide full author list
Instruments 2021, 5(4), 31; https://doi.org/10.3390/instruments5040031 - 29 Sep 2021
Cited by 133 | Viewed by 18178
Abstract
The Deep Underground Neutrino Experiment (DUNE) is an international, world-class experiment aimed at exploring fundamental questions about the universe that are at the forefront of astrophysics and particle physics research. DUNE will study questions pertaining to the preponderance of matter over antimatter in [...] Read more.
The Deep Underground Neutrino Experiment (DUNE) is an international, world-class experiment aimed at exploring fundamental questions about the universe that are at the forefront of astrophysics and particle physics research. DUNE will study questions pertaining to the preponderance of matter over antimatter in the early universe, the dynamics of supernovae, the subtleties of neutrino interaction physics, and a number of beyond the Standard Model topics accessible in a powerful neutrino beam. A critical component of the DUNE physics program involves the study of changes in a powerful beam of neutrinos, i.e., neutrino oscillations, as the neutrinos propagate a long distance. The experiment consists of a near detector, sited close to the source of the beam, and a far detector, sited along the beam at a large distance. This document, the DUNE Near Detector Conceptual Design Report (CDR), describes the design of the DUNE near detector and the science program that drives the design and technology choices. The goals and requirements underlying the design, along with projected performance are given. It serves as a starting point for a more detailed design that will be described in future documents. Full article
Show Figures

Figure 1

16 pages, 3800 KiB  
Article
Conservative Management of Medication-Related Osteonecrosis of the Jaws (MRONJ): A Retrospective Cohort Study
by Elena M. Varoni, Niccolò Lombardi, Giulio Villa, Alberto Pispero, Andrea Sardella and Giovanni Lodi
Antibiotics 2021, 10(2), 195; https://doi.org/10.3390/antibiotics10020195 - 17 Feb 2021
Cited by 35 | Viewed by 4964
Abstract
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a severe side effect of bisphosphonates and anti-resorptive drugs prescribed for treatment of severe osteoporosis, Paget’s disease, and bone malignancies. The aim of this study was to evaluate the clinical outcome of a combined pharmacological [...] Read more.
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a severe side effect of bisphosphonates and anti-resorptive drugs prescribed for treatment of severe osteoporosis, Paget’s disease, and bone malignancies. The aim of this study was to evaluate the clinical outcome of a combined pharmacological and surgical management strategy on patients affected by MRONJ. Materials and methods: Medical records of patients with MRONJ were retrospectively examined to collect clinical history data. Conservative management included an initial pharmacological phase with antibiotics and antiseptic agents, followed by surgical intervention to remove bone sequestrum. Primary outcomes were healing from MRONJ at short term (1 month after surgery) and at longer term (3 months after surgery). Secondary outcome was assessment of recurrences at longer-term follow-up. Results: Thirty-five patients were included in the study with mean follow-up of 23.86 ± 18.14 months. Seven cases showed spontaneous exfoliation of necrotic bone during pharmacological therapy, which in one case did not require any further intervention. At 1-month posttreatment, 31 out of 35 (88.5%) patients showed complete healing. The 25 patients who were followed for at least 3 months revealed a healing rate of 92% (23/25). Recurrences occurred in 7 patients out 23 who showed the long-term healing, after a mean period of 7.29 ± 3.45 months. The prognostic score (University of Connecticut Osteonecrosis Numerical Scale—UCONNS) was significantly higher (p = 0.01) in patients with poor healing as compared to complete healing, both at 1 and 3 months posttreatment. Conclusions: A MRONJ treatment approach based on a combined pharmacological and surgical treatment strategy showed a high rate of healing and few recurrences. Full article
(This article belongs to the Special Issue Antibiotic Treatment of Oral Infections)
Show Figures

Figure 1

21 pages, 383 KiB  
Article
The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The “ImpACT-COVID-19 for Patients” Multi-Centre Observational Study
by Giuseppe Deledda, Niccolò Riccardi, Stefania Gori, Sara Poli, Matteo Giansante, Eleonora Geccherle, Cristina Mazzi, Ronaldo Silva, Nicoletta Desantis, Ambra Mara Giovannetti, Alessandra Solari, Paolo Confalonieri, Licia Grazzi, Elena Sarcletti, Gabriella Biffa, Antonio Di Biagio, Carlo Sestito, Roland Keim, Alida M. R. Di Gangi Hermis, Mariantonietta Mazzoldi, Alessandro Failo, Anna Scaglione, Naida Faldetta, Patrizia Dorangricchia, Maria Moschetto, Hector Josè Soto Parra, Jennifer Faietti, Anna Di Profio, Stefano Rusconi, Andrea Giacomelli, Fabio Marchioretto, Filippo Alongi, Antonio Marchetta, Giulio Molon, Zeno Bisoffi and Andrea Anghebenadd Show full author list remove Hide full author list
Int. J. Environ. Res. Public Health 2021, 18(1), 340; https://doi.org/10.3390/ijerph18010340 - 5 Jan 2021
Cited by 16 | Viewed by 5546
Abstract
Psychological distress imposed by the SARS-CoV-2 outbreak particularly affects patients with pre-existing medical conditions, and the progression of their diseases. Patients who fail to keep scheduled medical appointments experience a negative impact on care. The aim of this study is to investigate the [...] Read more.
Psychological distress imposed by the SARS-CoV-2 outbreak particularly affects patients with pre-existing medical conditions, and the progression of their diseases. Patients who fail to keep scheduled medical appointments experience a negative impact on care. The aim of this study is to investigate the psychosocial factors contributing to the cancellation of medical appointments during the pandemic by patients with pre-existing health conditions. Data were collected in eleven Italian hospitals during the last week of lockdown, and one month later. In order to assess the emotional impact of the SARS-CoV-2 outbreak and the subject’s degree of psychological flexibility, we developed an ad hoc questionnaire (ImpACT), referring to the Acceptance and Commitment Therapy (ACT) model. The Impact of Event Scale-Revised (IES-R), the Depression, Anxiety and Stress Scale (DASS) and the Cognitive Fusion Questionnaire (CFQ) were also used. Pervasive dysfunctional use of experiential avoidance behaviours (used with the function to avoid thought, emotions, sensations), feelings of loneliness and high post-traumatic stress scores were found to correlate with the fear of COVID-19, increasing the likelihood of cancelling medical appointments. Responding promptly to the information and psychological needs of patients who cancel medical appointments can have positive effects in terms of psychological and physical health. Full article
24 pages, 4727 KiB  
Article
On the Synergy between Elemental Carbon and Inorganic Ions in the Determination of the Electrical Conductance Properties of Deposited Aerosols: Implications for Energy Applications
by Luca Ferrero, Alessandra Bigogno, Amedeo M. Cefalì, Grazia Rovelli, Luca D’Angelo, Marco Casati, Niccolò Losi and Ezio Bolzacchini
Appl. Sci. 2020, 10(16), 5559; https://doi.org/10.3390/app10165559 - 11 Aug 2020
Cited by 2 | Viewed by 2224
Abstract
The role of the elemental carbon (EC), in synergy with hygroscopic ionic species, was investigated to study the formation of electrical bridging phenomena once the aerosol deliquescence is achieved. Ambient aerosol samples were collected on hydrophobic surfaces in urban and rural sites in [...] Read more.
The role of the elemental carbon (EC), in synergy with hygroscopic ionic species, was investigated to study the formation of electrical bridging phenomena once the aerosol deliquescence is achieved. Ambient aerosol samples were collected on hydrophobic surfaces in urban and rural sites in Northern Italy; their conductance was measured in an Aerosol Exposure Chamber (AEC) while varying the relative humidity. An electric signal was detected on 64% of the collected samples with conductance values (11.20 ± 7.43 μS) above the failure threshold (1 μS) of printed circuit boards. The ionic content was higher for non-electrically conductive samples (43.7 ± 5.6%) than for electrically conductive ones (37.1 ± 5.6%). Conversely, EC was two times higher for electrically conductive samples (26.4 ± 4.1 μg cm−2; 8.4 ± 1.7%) than for non-electrical ones (12.0 ± 4.1 μg cm−2; 5.2 ± 1.9%) suggesting that the synergy between the ionic and carbonaceous fractions is necessary to promote a bridging phenomenon. Synthetic aerosols (EC only, saline only, mixed saline and EC) were generated in laboratory and their conductance was measured in the AEC to verify the ambient results. Only in case of a contemporary presence of both EC and ionic components the bridging phenomenon occurred in keeping with the theoretical deliquescence values of each salt (R2 = 0.996). Full article
(This article belongs to the Special Issue Combustion Aerosol)
Show Figures

Figure 1

8 pages, 1088 KiB  
Article
Actinomycosis of the Tongue: A Case Report and Review of Literature
by Fiorella D’Amore, Roberto Franchini, Laura Moneghini, Niccolò Lombardi, Giovanni Lodi, Andrea Sardella and Elena M. Varoni
Antibiotics 2020, 9(3), 124; https://doi.org/10.3390/antibiotics9030124 - 16 Mar 2020
Cited by 26 | Viewed by 6167
Abstract
Background: Actinomycosis of the tongue is an uncommon, suppurative infection of lingual mucosa, caused by actinomyces. The clinical diagnosis may present serious difficulties because of its ability to mimic other lesions, including both benign and malignant neoplasms. Methods: Here, we describe [...] Read more.
Background: Actinomycosis of the tongue is an uncommon, suppurative infection of lingual mucosa, caused by actinomyces. The clinical diagnosis may present serious difficulties because of its ability to mimic other lesions, including both benign and malignant neoplasms. Methods: Here, we describe the case of a 52-years-old patient affected by an asymptomatic, tumor-like tongue swelling, then diagnosed as actinomycosis. A review of tongue localization of actinomycosis is also reported, with emphasis on clinical findings and therapy. Results and Conclusion: Early diagnosis and treatment, with pus drainage and systemic antibiotic therapy, are pivotal to avoid severe and life-threatening complications. Full article
(This article belongs to the Special Issue Microbiological and Clinical Aspects of Actinomyces Infections)
Show Figures

Figure 1

20 pages, 1389 KiB  
Article
Assessing Agreement between miRNA Microarray Platforms
by Niccolò P. Bassani, Federico Ambrogi and Elia M. Biganzoli
Microarrays 2014, 3(4), 302-321; https://doi.org/10.3390/microarrays3040302 - 12 Dec 2014
Cited by 6 | Viewed by 5684
Abstract
Over the last few years, miRNA microarray platforms have provided great insights into the biological mechanisms underlying the onset and development of several diseases. However, only a few studies have evaluated the concordance between different microarray platforms using methods that took into account [...] Read more.
Over the last few years, miRNA microarray platforms have provided great insights into the biological mechanisms underlying the onset and development of several diseases. However, only a few studies have evaluated the concordance between different microarray platforms using methods that took into account measurement error in the data. In this work, we propose the use of a modified version of the Bland–Altman plot to assess agreement between microarray platforms. To this aim, two samples, one renal tumor cell line and a pool of 20 different human normal tissues, were profiled using three different miRNA platforms (Affymetrix, Agilent, Illumina) on triplicate arrays. Intra-platform reliability was assessed by calculating pair-wise concordance correlation coefficients (CCC) between technical replicates and overall concordance correlation coefficient (OCCC) with bootstrap percentile confidence intervals, which revealed moderate-to-good repeatability of all platforms for both samples. Modified Bland–Altman analysis revealed good patterns of concordance for Agilent and Illumina, whereas Affymetrix showed poor-to-moderate agreement for both samples considered. The proposed method is useful to assess agreement between array platforms by modifying the original Bland–Altman plot to let it account for measurement error and bias correction and can be used to assess patterns of concordance between other kinds of arrays other than miRNA microarrays. Full article
(This article belongs to the Special Issue Advances in Data Analysis Methods and Tools)
Show Figures

Figure 1

Back to TopTop